AZ says Calquence is a safer drug than ImbruvicaAstraZeneca’s fast-growing BTK inhibitor Calquence is already challenging class leader Imbruvica from Johnson & Johnson/AbbVie in the treatment Share XAZ says Calquence is a safer drug than Imbruvicahttps://pharmaphorum.com/news/az-says-calquence-is-a-safer-drug-than-imbruvica/
ASH: Lilly builds case for its BTK drug LOXO-305 in lymphomaEli Lilly’s buyout of Loxo Oncology last year has already yielded one approved drug, and it now has Share XASH: Lilly builds case for its BTK drug LOXO-305 in lymphomahttps://pharmaphorum.com/news/ash-lilly-builds-case-for-its-btk-drug-loxo-305-in-lymphoma/
AbbVie, J&J embed Imbruvica deeper in CLL therapy with new approvalAbbVie and Johnson & Johnson’s Imbruvica is already a mainstay of chronic lymphocytic leukaemia (CLL) therapy, but can Share XAbbVie, J&J embed Imbruvica deeper in CLL therapy with new approvalhttps://pharmaphorum.com/news/abbvie-jj-embed-imbruvica-deeper-in-cll-therapy-with-new-approval/
BeiGene’s Brukinsa fails to beat AbbVie/J&J’s Ibrutinib in WMBeiGene’s Brukinsa (zanubrutinib) has failed to outperform its class rival from Johnson & Johnson/AbbVie in the rare white Share XBeiGene’s Brukinsa fails to beat AbbVie/J&J’s Ibrutinib in WMhttps://pharmaphorum.com/news/beigenes-brukinsa-fails-to-beat-abbvie-jjs-ibrutinib-in-wm/
ASH19: AZ’s Calquence throws gauntlet down to ImbruvicaAstraZeneca’s resurgent cancer division could have another winner on its hands. Stellar data with newly-approved BTK inhibitor Calquence Share XASH19: AZ’s Calquence throws gauntlet down to Imbruvicahttps://pharmaphorum.com/news/ash19-azs-calquence-throws-gauntlet-down-to-imbruvica/
FDA nod for AZ’s Calquence sets up new Imbruvica showdownAbbVie and Johnson & Johnson are facing a challenge to their blockbuster chronic lymphocytic leukaemia drug Imbruvica from Share XFDA nod for AZ’s Calquence sets up new Imbruvica showdownhttps://pharmaphorum.com/news/fda-nod-for-azs-calquence-sets-up-new-imbruvica-showdown/
AbbVie and J&J claim new Imbruvica okay in USAbbVie and Johnson & Johnson’s Imbruvica has become the first chemo-free treatment for first-line chronic lymphocytic leukaemia (CLL) Share XAbbVie and J&J claim new Imbruvica okay in UShttps://pharmaphorum.com/news/abbvie-and-jj-claim-new-imbruvica-okay-in-us/
AbbVie and J&J’s Imbruvica fails pancreatic cancer testAbbVie and Johnson & Johnson’s hopes of adding pancreatic cancer to the repertoire of oncology blockbuster Imbruvica has Share XAbbVie and J&J’s Imbruvica fails pancreatic cancer testhttps://pharmaphorum.com/news/abbvie-and-jjs-imbruvica-fails-pancreatic-cancer-test/
China’s BeiGene delays US filing for rival to ImbruvicaBeiGene’s plans for an early approval for BTK inhibitor zanubrutinib in the US and to start challenging Janssen/AbbVie’s Share XChina’s BeiGene delays US filing for rival to Imbruvicahttps://pharmaphorum.com/news/chinas-beigene-delays-us-filing-for-rival-to-imbruvica/
